Celldex Therapeutics PE Ratio 2006-2021 | CLDX

Current and historical p/e ratio for Celldex Therapeutics (CLDX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Celldex Therapeutics PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Celldex Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 44.55 0.00
2021-06-30 33.44 $-1.67 0.00
2021-03-31 20.60 $-1.83 0.00
2020-12-31 17.52 $-2.14 0.00
2020-09-30 14.83 $-2.23 0.00
2020-06-30 13.00 $-2.62 0.00
2020-03-31 1.66 $-2.96 0.00
2019-12-31 2.23 $-3.63 0.00
2019-09-30 2.13 $-3.80 0.00
2019-06-30 2.68 $-3.65 0.00
2019-03-31 4.92 $-4.46 0.00
2018-12-31 2.97 $-15.65 0.00
2018-09-30 6.77 $-15.29 0.00
2018-06-30 7.55 $-17.69 0.00
2018-03-31 34.95 $-19.49 0.00
2017-12-31 42.60 $-11.09 0.00
2017-09-30 42.90 $-15.14 0.00
2017-06-30 37.05 $-16.49 0.00
2017-03-31 54.15 $-17.84 0.00
2016-12-31 53.10 $-18.89 0.00
2016-09-30 60.60 $-19.34 0.00
2016-06-30 65.85 $-19.79 0.00
2016-03-31 56.70 $-19.94 0.00
2015-12-31 235.20 $-19.64 0.00
2015-09-30 158.10 $-20.09 0.00
2015-06-30 378.30 $-19.94 0.00
2015-03-31 418.05 $-19.79 0.00
2014-12-31 273.75 $-19.79 0.00
2014-09-30 194.40 $-18.44 0.00
2014-06-30 244.80 $-18.14 0.00
2014-03-31 265.05 $-16.94 0.00
2013-12-31 363.15 $-15.44 0.00
2013-09-30 531.45 $-15.44 0.00
2013-06-30 234.15 $-14.84 0.00
2013-03-31 173.70 $-14.69 0.00
2012-12-31 100.65 $-15.29 0.00
2012-09-30 94.50 $-15.59 0.00
2012-06-30 77.63 $-15.89 0.00
2012-03-31 76.35 $-16.49 0.00
2011-12-31 39.00 $-17.09 0.00
2011-09-30 34.28 $-2.25 0.00
2011-06-30 53.25 $-2.40 0.00
2011-03-31 60.30 $-2.85 0.00
2010-12-31 61.80 $-1.35 0.00
2010-09-30 60.00 $-18.29 0.00
2010-06-30 68.40 $-20.84 0.00
2010-03-31 92.10 $-24.59 0.00
2009-12-31 70.05 $-28.79 0.00
2009-09-30 82.35 $-29.39 0.00
2009-06-30 117.30 $-30.14 0.00
2009-03-31 97.65 $-31.93 0.00
2008-12-31 118.80 $-57.42 0.00
2008-09-30 174.45 $-62.97 0.00
2008-06-30 218.40 $-68.08 0.00
2008-03-31 147.00 $-70.63 0.00
2007-12-31 90.00 $-50.40 0.00
2007-09-30 100.80 $-52.20 0.00
2007-06-30 149.40 $-54.00 0.00
2007-03-31 262.80 $-55.80 0.00
2006-12-31 241.20 $-50.40 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.130B $0.007B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86